Key result
Early changes in diastolic strain basal time during doxorubicin are linked to subsequent cardiotoxicity.
Why the study?
Although diastolic dysfunction is common among patients receiving cancer therapy, clear evidence is lacking that it predicts systolic dysfunction.
Does diastolic strain time predict doxorubicin-induced systolic dysfunction in patients with active breast cancer?
Cohort (n=69)
Does diastolic strain time predict doxorubicin-induced systolic dysfunction in patients with active breast cancer?
Change in diastolic strain time during doxorubicin therapy may serve as an early predictor of subsequent systolic dysfunction in breast cancer patients.
Answers are grounded in this paper and cite their sources.
Dst may support early cardiotoxicity monitoring in breast cancer; leaves open its predictive value for systolic dysfunction.
BACKGROUND: Although diastolic dysfunction is common among patients treated with cancer therapy, no clear evidence has been shown that it predicts systolic dysfunction. This study evaluated the correlation of diastolic strain time (Dst) with the routine echocardiography diastolic parameters and estimated its role in the early detection of cardiotoxicity among patients with active breast cancer. METHODS: Data were collected as part of the Israel Cardio-Oncology Registry (ICOR), a prospective registry enrolling all adult patients referred to the cardio-oncology clinic. All patients with breast cancer, planned for Doxorubicin therapy, were included. Echocardiography, including global longitudinal systolic strain (GLS) and Dst, was assessed at baseline before chemotherapy (T1), during Doxorubicin therapy (T2) and after the completion of Doxorubicin therapy (T3). Cardiotoxicity was determined by GLS relative reduction of ≥15%. Dst was assessed as the time measured (ms) of the myocardium lengthening during diastole. RESULTS: Among 69 patients, 67 (97.1%) were females with a mean age of 52 ± 13 years. Dst was significantly associated with the routine diastolic parameters. Significant GLS reduction was observed in 10 (20%) patients at T3. Both in a univariate and a multivariate analyses, the change in Ds basal time from T1 to T2 emerged to be significantly associated with GLS reduction at T3 (P < .04). CONCLUSIONS: Among breast cancer patients, Dst showed high correlation to the routine diastolic echocardiography parameters. Change in Ds basal time emerged associated with clinically significant systolic dysfunction as measured by GLS reduction.
No takes yet. Share an insight, caveat, or question.
Hochstadt et al. (2020) conducted a cohort in Active breast cancer (n=69). Diastolic strain time (Dst) was evaluated on Cardiotoxicity (GLS relative reduction of ≥15%) at T3 (p=<0.04). Change in diastolic strain basal time during early doxorubicin therapy was associated with subsequent cardiotoxicity among patients with breast cancer.
Synapse has enriched 10 related papers. Consider them for comparative context: